Brightsurf delivers daily science news discoveries, articles, and the latest scientific breakthroughs. Your trusted source for science news today, covering nature news, science & technology, and scientific discoveries from leading research institutions worldwide.
Researchers from HKUST develop 'one-pot' testing platform TEMPO for rapid, single-step nucleic acid testing, reaching attomolar sensitivity comparable to laboratory methods. The platform has potential applications in infectious disease surveillance and genetic screening.
The CIP2A protein regulates DNA repair during cell division and influences tumor response to radiotherapy. It controls Polθ activity and maintains its recruitment to damaged DNA sites through interaction with PP2A.
A new porous material has been developed to detect and adsorb copper ions, with a detection limit of 40.76 nM and a high adsorption capacity of 1902 mg/g. The material shows specific fluorescent recognition and cooperative adsorption capabilities, enabling efficient heavy metal monitoring and pollution treatment.
A survey of 365 Australian adolescents aged 10-15 found that those who began using social media at a younger age reported more symptoms of anxiety and depression. The study suggests that delaying children's first exposure to social media may be a promising policy for protecting mental health.
A new study reveals that China's retired electric vehicle batteries could unlock six billion tons of climate gains by 2050 if spatial mismatches are resolved. By prioritizing high-value utilization pathways like power storage and direct recycling, cost savings and emissions reductions can be delivered. The study suggests that establish...
Researchers have discovered a method to create complex polymer patterns using low-power lasers, enabling the production of water-repellent coatings and optical devices. The technique also has potential applications in data storage, electronics, and biomedical devices.
A clinical trial found that AZD5462, a new oral medication, was well-tolerated and improved cardiac remodeling and blood flow in patients with heart failure. The results suggest that AZD5462 may be a promising treatment option for patients with chronic heart failure.
Researchers have identified a new resistance gene, PsFwC9, that protects peas against Fusarium wilt, a devastating disease causing yield losses up to 30%. The gene, located on chromosome 4, confers resistance through a distinct mechanism, opening up new possibilities for understanding plant defense and stacking resistance genes.
KAIST researchers analyzed key challenges in microbial food industry and proposed growth strategies for next-generation protein market. The study emphasizes the importance of manufacturing readiness, market entry strategies, and regulatory compliance in commercializing microbial foods.
A new study found that 72% of Australian women wear a different size under US sizing and 65% under EU sizing. The researchers suggest that some women may be compensating for shoes that don't accommodate their foot width. The study highlights the need for more inclusive footwear sizing systems and clearer sizing information.
A one-year tailored exercise program significantly reduced atrial fibrillation (AF) burden and improved cardiorespiratory fitness in patients with non-permanent AF. Despite lack of significant improvements in quality of life, the exercise intervention showed meaningful benefits in measures of fitness and hospitalisations.
Plozasiran administered by subcutaneous injection every three months has shown substantial reductions in triglyceride levels, with a 78-80% decrease observed after one year. The treatment also demonstrated a significant reduction in acute pancreatitis events, with a 78% decrease in trial populations.
A recent study found that catheter ablation does not significantly improve quality of life related to atrial fibrillation, but reduces AF recurrence. The PVI-SHAM-AF trial showed that both catheter ablation and a sham procedure improved AF-related quality of life, with no significant difference between them.
Researchers found that gene silencer therapy may be beneficial for patients with transthyretin amyloid cardiomyopathy, with attenuated benefits observed when combined with TTR stabilizer therapy. The study will be presented at the European Society of Cardiology Congress in Munich, Germany.
A community-based trial in rural China found that intensive blood-pressure lowering intervention reduced dementia risk by 15% compared to usual care. The intervention also showed benefits in cognitive impairment and serious adverse events. This scalable approach may help reduce the increasing burden of dementia globally.
A large international study found that routine referrals to cardiologists or internists improved cholesterol levels in prostate cancer patients, but did not lead to fewer heart attacks, strokes, or cardiovascular deaths. Researchers noted that fewer participants experienced these complications than expected, making it harder to determi...
A new study finds that a TAVI-first strategy is noninferior to a PCI-first strategy in patients with severe aortic stenosis and concomitant coronary artery disease. The trial showed that fewer patients in the TAVI-first group ultimately underwent PCI, and life-threatening bleeding occurred at a lower rate with the TAVI-first strategy.
Transcatheter tricuspid valve repair improved heart failure hospitalization and all-cause mortality in patients with severe tricuspid regurgitation. The TRIC-I-HF trial demonstrated a significant benefit in reducing hard clinical outcomes, including quality-of-life improvements and sustained reductions in mortality.
The ACASA-TAVI trial found that non-vitamin K antagonist oral anticoagulants (NOACs) significantly reduced imaging signs of leaflet thrombosis by 45% compared to antiplatelet therapy after TAVI. NOAC monotherapy also demonstrated a comparable safety profile, with lower risk of severe bleeding events.
The TIME-HF trial found that a nurse-led intervention improving guideline-directed medical therapy uptake and clinical outcomes in patients with heart failure in India led to increased days alive and out of hospital and a 22% reduction in deaths at 2 years. This collaborative care model may serve as a blueprint for other settings with ...
A phase IIb trial found that AZD5462, an oral relaxin agonist, improved cardiac function in patients with heart failure, particularly at the lowest dose, with no safety concerns noted. The study suggests that AZD5462 may be a promising addition to existing therapies for heart failure.
A nationwide study found that early initiation of statins after type 2 diabetes diagnosis was associated with a 15% lower relative risk of dementia over 10 years. Statin treatment was also linked to a 10% lower risk of dementia in patients who initiated treatment between one and five years after diagnosis.
The H-HeFT trial found no significant difference in death or heart failure events with hydralazine–isosorbide dinitrate versus placebo in patients with heart failure and reduced ejection fraction. High treatment discontinuation rates emphasize the need for careful evaluation of hydralazine–isosorbide dinitrate's tolerability profile.
A large randomized trial and meta-analysis found no evidence that metformin reduces cardiovascular outcomes in patients with heart failure with reduced ejection fraction and diabetes. Metformin remains beneficial for glucose lowering but lacks cardioprotective benefits.
Researchers at KAIST have developed a low-cost smartphone-based technology to detect hidden cameras by analyzing reflections from objects. The technology, called SweepLED, uses deep learning-based analysis to distinguish camera lenses from ordinary objects, achieving 94% detection accuracy. The technology has potential to be developed ...
A virtual e-health system (VIRTUES) has been found to be as safe and effective as standard care for monitoring cardiac implantable electronic devices, with significant cost savings and patient satisfaction. The system uses transmission reports from the patient's device to provide real-time monitoring and communication with the physician.
The AIR-STEMI trial found that functional coronary angiography significantly reduced major cardiovascular events and complications by 38% and 37%, respectively, compared to conventional angiography. The study showed that this approach can improve current care for high-risk patient populations by selecting and treating only clinically i...
A digital strategy identified untreated patients with heart failure and invited them for specialist evaluation, resulting in a more than doubling of guideline-recommended SGLT2 inhibitor therapy. The approach showed promise in increasing timely access to effective treatments for this major public health issue.
A randomized trial found that digital outreach improved short-term statin refill rates among patients with cardiovascular disease or high cardiovascular risk who had fallen behind on their prescriptions. Adaptive, sequential health system outreach strategies support improved cardiovascular prevention in population health programs.
A new study confirms the safety of rapid heart attack testing but finds no reduction in emergency department stay length. The 0/1-hour pathway was compared to the standard 0/3-hour pathway and was found to be noninferior in terms of safety.
Remote exercise-based cardiac rehabilitation shows promise as an additional option for patients, but does not replace centre-based rehabilitation. The study found that remotely delivered exercise improved physical capacity and was used by a substantial proportion of patients, despite not increasing overall participation.
The REACT study reveals that 57.1% of participants aged 18 to 70 had atherosclerotic plaques, despite no symptoms or previous diagnosis. Most people with coronary atherosclerosis also had the disease in other arteries, making portable ultrasound devices a promising screening tool.
A new study found that atorvastatin reduces major cardiovascular events by 30% in people aged 70 and older without known cardiovascular disease, diabetes, or dementia. However, it did not improve disability-free survival. The results inform treatment guidelines for older adults, who are underrepresented in previous trials.
The AMUNDSEN trial found that evolocumab significantly improved LDL-cholesterol goal achievement after a heart attack, but did not show early cardiovascular benefits. Patients who received evolocumab had a higher rate of LDL-C goal attainment compared to standard care.
A phase 2 clinical trial found that a monoclonal antibody targeting interleukin-6 achieved sustained reductions in inflammation biomarkers for six months in patients with chronic kidney disease. The therapy, known as pacibekitug, was well-tolerated and showed favorable effects on additional biomarkers associated with cardiovascular risk.
Starting evolocumab before or during percutaneous coronary intervention for acute myocardial infarction significantly reduces LDL cholesterol levels. However, this strategy does not improve short-term clinical outcomes, including death and cardiovascular hospitalization, during the first year. The study suggests that lowering LDL chole...
Pacibekitug, a long-acting monoclonal antibody targeting interleukin-6, produced sustained reductions in inflammatory markers in patients with chronic kidney disease. The treatment also showed dose-dependent effects on other inflammatory markers, such as fibrinogen and lipoprotein(a).
Atrial fibrillation patients with prior intracranial haemorrhage face uncertain stroke prevention strategies. Edoxaban trial findings indicate a need for individualised decision-making, highlighting increased bleeding risk in this population.
A study found that silent atherosclerosis is prevalent in 57.1% of adults, increasing with age and affecting men earlier than women. Conventional risk assessment often misses this disease, highlighting the need for early imaging detection and potential precision medicine approaches.
Atrial fibrillation patients who have had a heart attack may be at increased risk of bleeding if given potent antiplatelet therapy combined with direct oral anticoagulants. The EPIDAURUS trial found no significant benefits regarding cardiovascular events, suggesting these treatments may not be necessary for this patient population.